Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $662000.0.

  • Artiva Biotherapeutics' Depreciation & Amortization (CF) rose 558.21% to $662000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 555.79%. This contributed to the annual value of $2.4 million for FY2024, which is 728.16% up from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Depreciation & Amortization (CF) of $662000.0 as of Q3 2025, which was up 558.21% from $641000.0 recorded in Q2 2025.
  • Over the past 5 years, Artiva Biotherapeutics' Depreciation & Amortization (CF) peaked at $662000.0 during Q3 2025, and registered a low of $500000.0 during Q2 2023.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $608500.0 (2024), whereas its average is $601200.0.
  • Examining YoY changes over the last 5 years, Artiva Biotherapeutics' Depreciation & Amortization (CF) showed a top increase of 2060.0% in 2024 and a maximum decrease of 336.7% in 2024.
  • Quarter analysis of 3 years shows Artiva Biotherapeutics' Depreciation & Amortization (CF) stood at $594000.0 in 2023, then grew by 3.37% to $614000.0 in 2024, then increased by 7.82% to $662000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $662000.0 in Q3 2025, compared to $641000.0 in Q2 2025 and $628000.0 in Q1 2025.